Eosinophilic annular erythema in childhood - Case report

Abstract

Eosinophilic annular erythema is a rare, benign, recurrent disease, clinically characterized by persistent, annular, erythematous lesions, revealing histopathologically perivascular infiltrates with abundant eosinophils. This report describes an unusual case of eosinophilic annular erythema in a 3-year-old female, requiring sustained doses of hydroxychloroquine to be adequately controlled.

Eosinophilic annular erythema is clinically characterized by central pigmentation reflecting basal melanosis: a clinicopathological study of 10 cases

“…As stated in the first report of eosinophilic annular erythema (EAE), the entity of EAE was proposed to describe annular skin lesions associated with tissue eosinophilia . To date, 25 cases of EAE have been reported in the English literature . EAE is characterized by the appearance of persistent annular or figurate lesions, a chronic course with recurrent relapse and recalcitrance to various treatments .…”

Eosinophilic annular erythema treated with dupilumab

“…The main histologic differential diagnosis is Wells syndrome. In contrast to Wells, in EAE, the eosinophilic infiltrate is confined to the dermis, and there is no granulomatous inflammation or flame figures …”

“…EAE is a benign, recurrent condition of unknown etiology that Peterson and Jarrat first described as annular erythema of infancy in 1981 . This rare condition, with fewer than 30 reports in the literature, is characterized by a relapsing‐remitting course of persistent annular and figurate urticarial plaques predominantly affecting the trunk and proximal extremities . Lesions resolve spontaneously after months to years and heal with no residual atrophy or scarring, although most reported patients exhibit recurrence …”

“…Histologically, there is marked eosinophilic infiltration of the dermis, accompanied by a lymphocytic perivascular or interstitial infiltrate . The main histologic differential diagnosis is Wells syndrome.…”

“…EAE is marked by its resistance to multiple treatments. Prednisolone and hydroxychloroquine are the therapeutic agents most frequently reported in the literature, but the majority of individuals who use them relapse . Additional single case reports have shown improvement with narrow‐band ultraviolet B, dapsone, and indomethacin, but indomethacin was discontinued after several doses because of associated syncope …”